Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Acetylcholinesterase

3

Butyrylcholinesterase

3

Muscle-type nicotinic acetylcholine receptor

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1951

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Myasthenia gravis

3

Neuromuscular blockade

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Diagnostic

3

Preventing

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Hoffman-La Roche

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

DRUG BANK

3

EPA CompTox

3

FDA UNII

3

PUBCHEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

EDROPHONIUM

70FP3JLY7N

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1951

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Butyrylcholinesterase

Muscle-type nicotinic acetylcholine receptor

Acetylcholinesterase

Conditions:

Neuromuscular blockade

Myasthenia gravis

Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment re...

quirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

EDROPHONIUM CHLORIDE

QO611KSM5P

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1951

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Butyrylcholinesterase

Muscle-type nicotinic acetylcholine receptor

Acetylcholinesterase

Conditions:

Neuromuscular blockade

Myasthenia gravis

Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment re...

quirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

EDROPHONIUM BROMIDE

KX008093VW

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1951

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Butyrylcholinesterase

Muscle-type nicotinic acetylcholine receptor

Acetylcholinesterase

Conditions:

Neuromuscular blockade

Myasthenia gravis

Edrophonium is a short and rapid-acting cholinergic drug. Chemically, edrophonium is ethyl (m-hydroxyphenyl) dimethylammonium. Edrophonium is used for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment re...

quirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. It is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1